A Practical Review of C-Peptide Testing in Diabetes
Open accessThe DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
Abstract
C-peptide is a widely used measure of pancreatic beta cell function. It is produced in equimolar amounts to endogenous insulin but is excreted at a more constant rate over a longer time. Methods of estimation include urinary and unstimulated and stimulated serum sampling. Modern assays detect levels of c-peptide which can be used to guide diabetes diagnosis and management. We explore the evidence behind the various tests available. We recommend the glucagon stimulation c-peptide testing owing to its balance of sensitivity and practicality. C-peptide levels are associated with diabetes type and duration of disease. Specifically a c-peptide level of less than 0.2 nmol/l is associated with a diagnosis of type 1 diabetes mellitus (T1DM). C-peptide level may correlate with microvascular and macrovascular complications and future use of insulin therapy, as well as likely response to other individual therapies. We explore the potential uses of c-peptide measurement in clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Measurement of the C-peptide, in the fasting state or in response to intravenous glucagon, can aid in instances in which it is difficult to differentiate between the diagnosis of type 1 and type 2 diabetes (5,511).”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [511]
In the citing paper
“C-peptide and insulin are both derived from proinsulin, with C-peptide being a valuable measure of insulin secretion and therefore pancreatic beta cell function.(17)”
From Putting humpty dumpty back together again: what does protein quantification mean in bottom-up proteomics? (2022) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Insulin Biosynthesis: Evidence for a Precursor
Steiner, D. F., Cunningham, D., Spigelman, L., & Aten, B. (1967) · Science · doi:10.1126/science.157.3789.697 · Cited by 712 · cited 1×
“31-amino-acid peptide c-peptide are produced in equal amounts [3, 4].”
BackgroundThe Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group (2016) · Diabetes Care · doi:10.2337/dc15-1990 · Cited by 712
Steffes, M. W., Sibley, S., Jackson, M., & Thomas, W. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.832 · Cited by 695
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.gl · Cited by 629
The clinical utility of C‐peptide measurement in the care of patients with diabetes
Jones, A. G., & Hattersley, A. T. (2013) · Diabetic Medicine · doi:10.1111/dme.12159 · Cited by 628 · cited 2×
“assessing pancreatic beta cell function [1, 2].”
BackgroundPalmer, J. P., Fleming, G. A., Greenbaum, C. J., Herold, K. C., Jansa, L. D., Kolb, H., Lachin, J. M., Polonsky, K. S., Pozzilli, P., Skyler, J. S., et al. (2004) · Diabetes · doi:10.2337/diabetes.53.1.250 · Cited by 491
A1C Variability and the Risk of Microvascular Complications in Type 1 Diabetes
Kilpatrick, E. S., Rigby, A. S., & Atkin, S. L. (2008) · Diabetes Care · doi:10.2337/dc08-0864 · Cited by 420
C-peptide Response to Glucagon: A Test for the Residual β-cell Function in Diabetes Mellitus
Faber, O. K., & Binder, C. (1977) · Diabetes · doi:10.2337/diab.26.7.605 · Cited by 386
Handelsman, Y., Henry, R. R., Bloomgarden, Z. T., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Ferrannini, E., Fonseca, V. A., Garber, A. J., Grunberger, G., et al. (2016) · Endocrine Practice · doi:10.4158/ep161292.ps · Cited by 358 · cited 1×
“Unfortunately, low c-peptide is not a consistent finding in patients on SGLT-2 inhibitors who have ketoacidosis [52, 53].”
BackgroundShields, B. M., McDonald, T. J., Ellard, S., Campbell, M. J., Hyde, C., & Hattersley, A. T. (2012) · Diabetologia · doi:10.1007/s00125-011-2418-8 · Cited by 335 · cited 1×
“The ‘‘Diabetes Diagnostics’’ app has been created by the University of Exeter diabetes research team as a convenient resource for the diagnosis of MODY and other types of diabetes on the basis of clinical criteria according to national and international guidelines in addition to c-peptide interpretation [37, 38].”
MethodOral Glucose Tolerance Test Minimal Model Indexes of β-Cell Function and Insulin Sensitivity
Breda, E., Cavaghan, M. K., Toffolo, G., Polonsky, K. S., & Cobelli, C. (2001) · Diabetes · doi:10.2337/diabetes.50.1.150 · Cited by 320
Fall in C-Peptide During First 2 Years From Diagnosis
Greenbaum, C. J., Beam, C. A., Boulware, D., Gitelman, S. E., Gottlieb, P. A., Herold, K. C., Lachin, J. M., McGee, P., Palmer, J. P., Pescovitz, M. D., et al. (2012) · Diabetes · doi:10.2337/db11-1538 · Cited by 319
Greenbaum, C. J., Mandrup-Poulsen, T., McGee, P. F., Battelino, T., Haastert, B., Ludvigsson, J., Pozzilli, P., Lachin, J. M., Kolb, H., & The Type 1 Diabetes Trial Net Research Group and the European C-Peptide Trial Study Group (2008) · Diabetes Care · doi:10.2337/dc07-2451 · Cited by 285 · cited 11×
“Two parallel randomized trials by the TrialNet group and by the European C-peptide Trial (ECPT) found moderately superior rises in peak response with the MMTT [19].”
BackgroundMethodInfluentialLachin, J. M., McGee, P., Palmer, J. P., & for the DCCT/EDIC Research Group (2014) · Diabetes · doi:10.2337/db13-0881 · Cited by 283
Prevalence of detectable C-peptide according to age at diagnosis and duration of type 1 diabetes
Davis, A. K., DuBose, S. N., Haller, M. J., Miller, K. M., DiMeglio, L. A., Bethin, K. E., Goland, R. S., Greenberg, E. M., Liljenquist, D. R., Ahmann, A. J., et al. (2015) · Diabetes Care · doi:10.2337/dc14-1952 · Cited by 261 · cited 1×
“A higher percentage of detectable c-peptide has been found in those with T1DM aged older than 18 years, compared to those younger than 18 years [34].”
BackgroundJohansson, B. ‐., Borg, K., Fernqvist‐Forbes, E., Kernell, A., Odergren, T., & Wahren, J. (2000) · Diabetic Medicine · doi:10.1046/j.1464-5491.2000.00274.x · Cited by 257 · cited 1×
“Some preliminary randomized controlled trials demonstrate that giving subcutaneous c-peptide alongside insulin to individuals with T1DM may ameliorate microvascular complications, such as albuminuria and autonomic nerve dysfunction [62, 63].”
BackgroundTHE DCCT RESEARCH GROUP (1987) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-65-1-30 · Cited by 220
Wang, L., Lovejoy, N. F., & Faustman, D. L. (2012) · Diabetes Care · doi:10.2337/dc11-1236 · Cited by 192
Amelioration of Sensory Nerve Dysfunction by C-Peptide in Patients With Type 1 Diabetes
Ekberg, K., Brismar, T., Johansson, B.-L., Jonsson, B., Lindström, P., & Wahren, J. (2003) · Diabetes · doi:10.2337/diabetes.52.2.536 · Cited by 185
Jones, A. G., McDonald, T. J., Shields, B. M., Hill, A. V., Hyde, C. J., Knight, B. A., & Hattersley, A. T. (2016) · Diabetes Care · doi:10.2337/dc15-0258 · Cited by 178
Madsbad, S., Krarup, T., McNair, P., Christiansen, C., Faber, O. K., Transbøl, I., & Binder, C. (1981) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1981.tb09793.x · Cited by 170 · cited 3×
“Further studies have demonstrated that c-peptide levels following GST are a consistently sensitive measure of beta cell function, which may be associated with diabetes type and future use of insulin [9, 19, 23, 24].”
BackgroundSacks, D. B., Arnold, M., Bakris, G. L., Bruns, D. E., Horvath, A. R., Kirkman, M. S., Lernmark, A., Metzger, B. E., & Nathan, D. M. (2011) · Diabetes Care · doi:10.2337/dc11-9997 · Cited by 170 · cited 9×
“In a retrospective study of insulin-treated individuals with T2DM, time to insulin prescription in individuals with an MMTT c-peptide of at most 0.2 nmol/l (suggesting absolute insulin deficiency) was 2.5 (1.5–3) years compared to 6 (3–10.75) years for those with a mixed meal stimulated c-peptide of greater than 0.2 n…”
InfluentialHattersley, A., Bruining, J., Shield, J., Njolstad, P., & Donaghue, K. (2006) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2006.00217.x · Cited by 140
Besser, R. E. J., Shepherd, M. H., McDonald, T. J., Shields, B. M., Knight, B. A., Ellard, S., & Hattersley, A. T. (2011) · Diabetes Care · doi:10.2337/dc10-1293 · Cited by 133 · cited 12×
“CSII continuous subcutaneous insulin infusion, MODY maturity-onset diabetes of the young, LADA latent autoimmune diabetes of adults The diabetes control and complications trial (DCCT) was the landmark study which helped generate the targets we presently use for T1DM.”
MethodInfluentialBhatt, M. P., Lim, Y.-C., Hwang, J., Na, S., Kim, Y.-M., & Ha, K.-S. (2013) · Diabetes · doi:10.2337/db12-0293 · Cited by 132 · cited 1×
“C-peptide has been shown in vitro to inhibit endothelial cell reactive oxygen species (ROS) formation in the presence of hyperglycemia [60, 61].”
BackgroundLow levels of C‐peptide have clinical significance for established Type 1 diabetes
Kuhtreiber, W. M., Washer, S. L. L., Hsu, E., Zhao, M., Reinhold, P., Burger, D., Zheng, H., & Faustman, D. L. (2015) · Diabetic Medicine · doi:10.1111/dme.12850 · Cited by 131 · cited 2×
“0001) with a younger age of onset (less than 10 years) resulting in a far more rapid c-peptide decline [6].”
BackgroundShields, B. M., Peters, J. L., Cooper, C., Lowe, J., Knight, B. A., Powell, R. J., Jones, A., Hyde, C. J., & Hattersley, A. T. (2015) · BMJ Open · doi:10.1136/bmjopen-2015-009088 · Cited by 126 · cited 1×
“A recent systematic review supported the diagnostic utility of c-peptide, recommending its use as the principal baseline measure of insulin deficiency [75].”
BackgroundPhysiological effects and therapeutic potential of proinsulin C-peptide
Yosten, G. L. C., Maric-Bilkan, C., Luppi, P., & Wahren, J. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00130.2014 · Cited by 123
Landin‐Olsson, M., NILSSON, K. O., Lernmark, Å., & Sundkvist, G. (1990) · Diabetologia · doi:10.1007/bf00404145 · Cited by 120 · cited 1×
“There is limited evidence in the literature about whether c-peptide can effectively predict whether patients require insulin [23, 39].”
Background(2004) · Diabetes · doi:10.2337/diabetes.53.7.1934 · Cited by 120
Blüher, M., Lübben, G., & Paschke, R. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.825 · Cited by 117
Madsbad, S., Faber, O. K., Binder, C., McNair, P., Christiansen, C., & Transbøl, I. (1978) · Diabetes · doi:10.2337/diab.27.1.s262 · Cited by 108
Gjessing, H. J., Matzen, L. H., FABER, O. K., & Fr�land, A. (1989) · Diabetologia · doi:10.1007/bf00265547 · Cited by 107 · cited 3×
“Further studies have demonstrated that c-peptide levels following GST are a consistently sensitive measure of beta cell function, which may be associated with diabetes type and future use of insulin [9, 19, 23, 24].”
BackgroundTang, X., Li, S., Wang, Y., Wang, M., Yin, Q., Mu, P., Lin, S., Qian, X., Ye, X., & Chen, Y. (2016) · Clinica Chimica Acta · doi:10.1016/j.cca.2016.08.004 · Cited by 100
Fasting Serum C‐Peptide Levels Predict Cardiovascular and Overall Death in Nondiabetic Adults
Patel, N., Taveira, T. H., Choudhary, G., Whitlatch, H. B., & Wu, W. (2012) · Journal of the American Heart Association · doi:10.1161/jaha.112.003152 · Cited by 89
Hermann, L. S., Scherstén, B., & Melander, A. (1994) · Diabetic Medicine · doi:10.1111/j.1464-5491.1994.tb00253.x · Cited by 87 · cited 1×
“Higher MMTT stimulated c-peptide has been shown to be present in patients who respond to metformin and glibenclamide in combination but GST c-peptide did not predict response to glibenclamide alone [42, 43].”
BackgroundBo, S., Gentile, L., Castiglione, A., Prandi, V, Canil, S., Ghigo, E., & Ciccone, G. (2012) · European Journal of Endocrinology · doi:10.1530/eje-12-0085 · Cited by 85
Random C-peptide in the classification of diabetes
B. Berger, G. S. (2000) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365510050216411 · Cited by 85 · cited 1×
“rCP has been shown to correlate with fasting c-peptide (fCP) and post glucagon stimulation test (GST) samples in subjects with well-defined type 1 or type 2 diabetes [16].”
BackgroundCifarelli, V., Geng, X., Styche, A. J., Lakomy, R., Trucco, M., & Luppi, P. (2011) · Diabetologia · doi:10.1007/s00125-011-2251-0 · Cited by 78 · cited 1×
“C-peptide has been shown in vitro to inhibit endothelial cell reactive oxygen species (ROS) formation in the presence of hyperglycemia [60, 61].”
BackgroundGuidelines for Intervention Trials in Subjects With Newly Diagnosed Type 1 Diabetes
Greenbaum, C. J., Harrison, L. C., & on behalf of the Immunology of Diabetes Society (2003) · Diabetes · doi:10.2337/diabetes.52.5.1059 · Cited by 76
McDonald, T. J., Knight, B. A., Shields, B. M., Bowman, P., Salzmann, M. B., & Hattersley, A. T. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2009.129312 · Cited by 75 · cited 2×
“In subjects with normal glucose tolerance urinary c-peptide to creatinine ratio (UCPCR) has been shown to correlate well with 24 h urinary c-peptide [5].”
BackgroundHope, S. V., Knight, B. A., Shields, B. M., Hattersley, A. T., McDonald, T. J., & Jones, A. G. (2016) · Diabetic Medicine · doi:10.1111/dme.13142 · Cited by 68 · cited 1×
“91) in insulin-treated subjects with diabetes, but levels of rCP out of this range require confirmation by another method [17].”
MethodKramer, C. K., Choi, H., Zinman, B., & Retnakaran, R. R. (2014) · Diabetes Care · doi:10.2337/dc13-2591 · Cited by 67 · cited 1×
“Lower levels of c-peptide and decreased beta cell function have been linked to greater levels of glucose variability [20, 56].”
BackgroundOkuno, Y., Komada, H., Sakaguchi, K., Nakamura, T., Hashimoto, N., Hirota, Y., Ogawa, W., & Seino, S. (2013) · Metabolism · doi:10.1016/j.metabol.2013.05.022 · Cited by 62
Serum C-peptide levels and risk of death among adults without diabetes mellitus
Min, J., & Min, K. (2013) · Canadian Medical Association Journal · doi:10.1503/cmaj.121950 · Cited by 56
Hirai, F. E., Moss, S. E., Klein, B. E. K., & Klein, R. (2008) · Diabetes Care · doi:10.2337/dc07-1161 · Cited by 54
Kim, S. A., Shim, W. H., Lee, E. H., Lee, Y. M., Beom, S. H., Kim, E. S., Yoo, J. S., Nam, J. S., Cho, M. H., Park, J. S., et al. (2011) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2011.35.2.159 · Cited by 50
EDTA Improves Stability of Whole Blood C-Peptide and Insulin to Over 24 Hours at Room Temperature
McDonald, T. J., Perry, M. H., Peake, R. W. A., Pullan, N. J., O’Connor, J., Shields, B. M., Knight, B. A., & Hattersley, A. T. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042084 · Cited by 49 · cited 1×
“However, c-peptide sample collection for c-peptide determination in whole blood in EDTA prepared tubes is stable at room temperature for up to 24 h [11].”
BackgroundArıkan, E., Sabuncu, T., Özer, E. M., & Hatemi, H. (2005) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2005.02.004 · Cited by 48
Inpatient Glycemic Variability and Long-Term Mortality in Hospitalized Patients with Type 2 Diabetes
Timmons, J. G., Cunningham, S. G., Sainsbury, C. A. R., & Jones, G. C. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.06.013 · Cited by 45
Self-citationKim, Y. M., Cha, B. S., Kim, D. J., Choi, S. H., Kim, S. K., Ahn, C. W., Lim, S.-K., Kim, K. R., Huh, K. B., & Lee, H. C. (2005) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2004.05.001 · Cited by 43 · cited 1×
“High fCP is associated with response to the thiazolidinediones, rosiglitazone and pioglitazone, which is in keeping with their action of reducing insulin resistance [44, 45].”
BackgroundC-peptide reserve in insulin-dependent diabetes
Mirel, R. D., Ginsberg‐Fellner, F., Horwitz, D. L., & Rayfield, E. J. (1980) · Diabetologia · doi:10.1007/bf00275266 · Cited by 43 · cited 1×
“Which method of c-peptide collection is most clinically useful? GST has been shown to be superior in sensitivity to use of glucose or tolbutamide as substrates, with a twofold higher mean increase in c-peptide response [13].”
MethodMarx, N., Silbernagel, G., Brandenburg, V., Burgmaier, M., Kleber, M. E., Grammer, T. B., Winkelmann, B. R., Boehm, B. O., & März, W. (2013) · Diabetes Care · doi:10.2337/dc12-1211 · Cited by 41
C-peptide as a risk factor of coronary artery disease in the general population
de León, A. C., García, J. G. O., Marcelino-Rodríguez, I., González, D. A., Sánchez, J. J. A., Díaz, B. B., Coello, S. D., Bertoméu, V., Jaime, A. A., & Pérez, M. D. C. R. (2015) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114564900 · Cited by 41
Bowman, P., McDonald, T. J., Shields, B. M., Knight, B. A., & Hattersley, A. T. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2011.03428.x · Cited by 40 · cited 1×
“Urinary c-peptide (UCP) is a non-invasive test, which can be performed in an outpatient setting [8].”
BackgroundThe Role of C-Peptide Levels in Screening for Latent Autoimmune Diabetes in Adults
Bell, D. S. H., & Ovalle, F. (2004) · American Journal of Therapeutics · doi:10.1097/01.mjt.0000102372.28723.2b · Cited by 29
Trischitta, V., Italia, S., Raimondo, M., Guardabasso, V., Licciardello, C., Runello, F., Mazzarino, S., Sangiorgi, L., Anello, M., & Vigneri, R. (1998) · Journal of Endocrinological Investigation · doi:10.1007/bf03348039 · Cited by 28
Takabe, M., Matsuda, T., Hirota, Y., Hashimoto, N., Nakamura, T., Sakaguchi, K., Ogawa, W., & Seino, S. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.09.036 · Cited by 27 · cited 1×
“Better insulin response to glucose is seen in those patients taking liraglutide with higher GST c-peptide levels [49].”
BackgroundThe impact of gender on urine C-peptide creatinine ratio interpretation
Thomas, N. J., Shields, B. M., Besser, R. E. J., Jones, A. G., Rawlingson, A., Goodchild, E., Leighton, C., Bowman, P., Shepherd, M. H., Knight, B., et al. (2012) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1258/acb.2011.011164 · Cited by 27
Thong, K. Y., McDonald, T. J., Hattersley, A. T., Blann, A. D., Ramtoola, S., Duncan, C., Carr, S. V., Adamson, K., Nayak, A., Khurana, R., et al. (2013) · Diabetic Medicine · doi:10.1111/dme.12367 · Cited by 25 · cited 1×
“The clinical relevance of this finding is confirmed by studies showing that fCP and post-meal UCPCR both predict reduction of HbA1c following initiation of treatment with an GLP-1 agonist [50, 51].”
BackgroundKoskinen, P. J., Viikari, J. S. A., & Irjala, K. M. A. (1988) · Diabetes Care · doi:10.2337/diacare.11.4.318 · Cited by 24 · cited 2×
“Further studies have demonstrated that c-peptide levels following GST are a consistently sensitive measure of beta cell function, which may be associated with diabetes type and future use of insulin [9, 19, 23, 24].”
BackgroundUrinary C‐peptide creatinine ratio detects absolute insulin deficiency in Type 2 diabetes
Hope, S. V., Jones, A. G., Goodchild, E., Shepherd, M. H., Besser, R. E. J., Shields, B. M., McDonald, T. J., Knight, B., & Hattersley, A. T. (2013) · Diabetic Medicine · doi:10.1111/dme.12222 · Cited by 23 · cited 1×
“Time to insulin treatment may also be associated with c-peptide response [40].”
BackgroundPikkemaat, M., Melander, O., Mölstad, S., Garberg, G., & Boström, K. B. (2014) · Diabetic Medicine · doi:10.1111/dme.12608 · Cited by 20
Oh, T. J., Jung, H. S., Bae, J. H., Kim, Y. G., Park, K. S., Cho, Y. M., Park, K. S., & Kim, S. Y. (2013) · Journal of Korean Medical Science · doi:10.3346/jkms.2013.28.6.881 · Cited by 17
Methodological Aspects on C‐peptide Measurements
Ludvigsson, J. (1983) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1983.tb08548.x · Cited by 16
M.Kulkarni, C., & Patil, S. M. (2016) · International Journal of Pharma and Bio Sciences · doi:10.22376/ijpbs.2016.7.4.b443-446 · Cited by 14 · cited 2×
“assessing pancreatic beta cell function [1, 2].”
BackgroundThe C-peptide response to a standard mixed meal in a group of Brazilian type 1 diabetic patients
Pozzan, R., Dimetz, T., Gazolla, H. M., & Gomes, M. B. (1997) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x1997001000005 · Cited by 13 · cited 1×
“Venous blood c-peptide levels can be measured in the random, fasting, or stimulated state [12].”
BackgroundSujesh Kumar, N., & Subhakumari, K. N. (2015) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-015-0451-8 · Cited by 12 · cited 10×
“In a retrospective study of insulin-treated individuals with T2DM, time to insulin prescription in individuals with an MMTT c-peptide of at most 0.2 nmol/l (suggesting absolute insulin deficiency) was 2.5 (1.5–3) years compared to 6 (3–10.75) years for those with a mixed meal stimulated c-peptide of greater than 0.2 n…”
ResultInfluentialC-Peptide Levels Predict the Effectiveness of Dipeptidyl Peptidase-4 Inhibitor Therapy
Demir, Ş., Temizkan, Ş., & Sargın, M. (2016) · Journal of Diabetes Research · doi:10.1155/2016/4509603 · Cited by 9
SGLT2 inhibitors and the risk of diabetic ketoacidosis
Redford, C., Doherty, L., & Smith, J. C. (2015) · Practical Diabetes · doi:10.1002/pdi.1969 · Cited by 7 · cited 1×
“Unfortunately, low c-peptide is not a consistent finding in patients on SGLT-2 inhibitors who have ketoacidosis [52, 53].”
BackgroundClinical care and other categories posters: hypoglycaemia
Hope, S., Knight, B. A., Shields, B. M., Strain, D., Hattersley, A. T., & Jones, A. G. (2016) · Diabetic Medicine · doi:10.1111/dme.35_13048 · Cited by 3 · cited 2×
“The MMTT has been advocated as the ‘‘gold standard’’ of stimulation testing owing to excellent sensitivity in detecting residual insulin secretion [7, 19, 20].”
BackgroundImportance of adherance to yoga in management of type 2 diabetes
Kumar, G., Jagannathan, A., & Sridhar, M. K. (2015) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-015-0351-y · Cited by 2
(2016) · Diabetic Medicine · doi:10.1111/dme.12907 · Cited by 1
Cited by
Clinical and Laboratory Standards Institute
(2019) · Springer Reference Medizin · doi:10.1007/978-3-662-48986-4_300416 · Cited by 5,091
Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints
Chang, L.-S., Barroso-Sousa, R., Tolaney, S. M., Hodi, F. S., Kaiser, U. B., & Min, L. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00006 · Cited by 532
(2019) · Springer Reference Medizin · doi:10.1007/978-3-662-48986-4_310898 · Cited by 473
CAH (Congenital Adrenal Hyperplasia)-Screening
(2019) · Springer Reference Medizin · doi:10.1007/978-3-662-48986-4_300351 · Cited by 368
Sacks, D. B., Arnold, M., Bakris, G. L., Bruns, D. E., Horvath, A. R., Lernmark, Å., Metzger, B. E., Nathan, D. M., & Kirkman, M. S. (2023) · Diabetes Care · doi:10.2337/dci23-0036 · Cited by 351
Metadata
- Authors
- Leighton, E., Sainsbury, C. A., & Jones, G. C.
- Affiliations
- Gartnavel General Hospital (GB)
- Corresponding author
- Jones, Gregory C.
- Venue
- Diabetes Therapy
- Published
- 2017-05-08
- Volume
- 8
- Issue
- 3
- Pages
- 475-487
- ISSN
- 1869-6953 (ISSN-L)
- 1869-6961
- PMC
- PMC5446389
- OpenAlex
- W2612702080
- Semantic Scholar
- 201713a9dc7f149a96676695027ce61eb08fc4d3
- Cited by
- 773
- References
- 74
- Citations by year
- 2026: 41 · 2025: 51 · 2024: 56 · 2023: 64 · 2022: 79 · 2021: 56 · 2020: 46 · 2019: 356 · 2018: 20 · 2017: 3
- FWCI
- 14.91
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by/4.0 (tdm)
- Locations
- Diabetes Therapy (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- beta-cell function, type 1 diabetes, glucagon stimulation test, diabetes diagnosis, diabetes management, microvascular complications, macrovascular complications, insulin therapy, disease duration
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
